Arrowhead quarterly net loss widens to $173.1 million as revenue falls to $2.5 million
Arrowhead Pharmaceuticals reported results for the fiscal 2025 first quarter ended December 31, 2024. Revenue was $2.5 million versus $3.551 million a year earlier, and the net loss attributable to the company widened to $173.1 million, or $1.39 per diluted share, from $132.9 million, or $1.24 per share. The company said it is funded into 2028 and cited the Sarepta licensing agreement and the plozasiran NDA acceptance as recent progress.
Key points
- Revenue of $2.5 million for the quarter, compared with $3.551 million a year earlier
- Net loss attributable to Arrowhead of $173.1 million, or $1.39 per diluted share, versus $132.9 million, or $1.24 per share, a year earlier
- Total cash resources of $552.9 million at December 31, 2024, down from $681.0 million at September 30, 2024
- Sarepta agreement provides $825 million upon closing, including $500 million in cash and a $325 million equity investment
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:17 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 10, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.